Posts
Advanced Therapy Medicinal Products (ATMPs) offer a real and
tangible hope for many different chronic illnesses for which there currently
are no or limited therapeutic options. The science and technology that support
these products are developing rapidly and therefore the products that are on
the market today will undoubtedly continue to improve and grow in effectiveness
and capability over time. Patients around the world are now beginning to
experience the benefits of these improved products. One such product is Stem
Cell Therapy, which uses stem cells from healthy cells taken from the patient's
own body.
Market Dynamics
High prevalence of Alzheimer’s disease is expected to propel
growth of the
advanced therapy medicinal products market. For instance, According to the
data from Alzheimer's Association, around 5.7 million people in the U.S. were
suffering from Alzheimer’s disease in 2018. Moreover, increasing adoption of gene therapy
is also expected to aid in growth of the market. For instance, in March 2020, AVROBIO,
Inc., a clinical-stage gene therapy company, announced that a second patient in
the AVR-RD-04 Phase 1/2 clinical trial in cystinosis has been enrolled and has
completed apheresis.
Development and commercialization of investigational RNAi
therapeutics is expected to offer lucrative growth opportunities for players in
the advanced therapy medicinal products market. For instance, in April 2020, Alnylam
Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for the
development and commercialization of investigational RNAi therapeutics for the
treatment of alpha-1 antitrypsin deficiency-associated liver disease. Moreover,
R&D in CAR-T cell production is also expected to aid in growth of the
market. For instance, in May 2020, researchers from University Hospital
Heidelberg, Germany, reported that sufficient yield of lymphocytes for CAR-T
cell production is feasible also for patients with low peripheral blood counts.
Among regions, North America is expected to witness significant
growth in the advanced therapy medicinal products market, owing to high
prevalence of cancer in the region. For instance, according to the American
Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases
diagnosed and 606,880 cancer deaths in the U.S.
Competitive Analysis
Major players operating the advanced therapy medicinal products
market include, Uniqure, Pfizer, Inc., Bluebird Bio Inc., BioMarin
Pharmaceutical, Novartis AG, GE Healthcare, Shire Biotechnology, and Kite
Pharma.
July 2019: Pfizer Inc. acquired Array BioPharma Inc. with the aim
to advance breakthrough science for the discovery, development and
commercialization of targeted small molecule medicines to treat cancer and
other diseases of high unmet need.
In-depth Report on Advanced Therapy Medicinal Products Market by
Coherent Market
No comments:
Post a Comment